DKCM
IMVT icon

Davidson Kempner Capital Management’s Immunovant IMVT Stock Holding History

Davidson Kempner Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-524,400
Closed -$5.13M – 179
2019
Q3 		$5.13M Buy
+524,400
New +$5.18M 0.1% 102

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Davidson Kempner Capital Management's IMVT Position: Q4 2019 in Review

Davidson Kempner Capital Management sold out of Immunovant (IMVT) in Q4 2019, closing a stake of 524,400 shares — an estimated $5.13M sold.

Davidson Kempner Capital Management first reported a position in IMVT in Q3 2019 and held it in 1 quarter. The position peaked at $5.13M in Q3 2019. 24 funds tracked by Wall St. Rank hold IMVT as of Q4 2019.

  • Davidson Kempner Capital Management reported no remaining Immunovant position as of Q4 2019 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 524,400 Immunovant shares in Q4 2019, an estimated $5.13M.
  • Davidson Kempner Capital Management first reported a position in Immunovant in Q3 2019 and held it in 1 quarter.
  • Davidson Kempner Capital Management's Immunovant position peaked at $5.13M in Q3 2019.
  • 24 funds tracked by Wall St. Rank held Immunovant as of Q4 2019.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.